Skip to content

The application of noninvasive positive pressure ventilation optimized parameter strategy in acute exacerbation of chronic obstructive pulmonary disease

The application of noninvasive positive pressure ventilation optimized parameter strategy in acute exacerbation of chronic obstructive pulmonary disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800016742
Enrollment
Unknown
Registered
2018-06-21
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

Optimized group:Noninvasive positive pressure ventilation under the optimization of noninvasive positive pressure ventilation parameter strategy+ oxygen therapy
control group:Noninvasive positive pressure ventilation (clinical experience) + oxygen therapy
Reference group (Guangzhou Panyu Central Hospital):Noninvasive positive pressure ventilation (clinical experience) + oxygen therapy

Sponsors

State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affliated Hospital of Guangzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40-80 years old; 2. Meet COPD diagnostic criteria; 3. The diagnosis was in line with AECOPD (defined as an acute change in a patients baseline dyspnoea, cough and/or sputum beyond day-today variability sufficient to warrant a change in therapy), and accompanied by respiratory acidosis (pH = 7.35, PaCO2> 50 mmHg).

Exclusion criteria

Exclusion criteria: 1) cardiac and respiratory arrest; 2) progressively worsening disease in spite of NIV administration; 3) the need to protect the airways; 4) hemodynamic instability (for example, heart rate < 50 beats/minute with loss of alertness, and/or systolic blood pressure < 70 mmHg); 5) agitation and inability to tolerate the mask; 6)Excludes malignant tumors, severe bronchiectasis , pulmonary embolism and other patients.

Design outcomes

Primary

MeasureTime frame
Arterial blood pH;

Secondary

MeasureTime frame
Arterial blood carbon dioxide partial pressure(PaCO2);Arterial blood oxygen partial pressure(PaO2);Respiratory rate;tidal volume (Vt);Failure rate;Peripheral oxygen saturation(SpO2);Heart rate;

Countries

China

Contacts

Public ContactChen Rongchang

State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affliated Hospital of Guangzhou Medical University

chenrc@vip.163.com+86 20 8306 2882

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026